Tardive Dyskinesia

Tardive dyskinesia (TD) is an abnormal involuntary movement disorder that arises as a common adverse effect in patients using antipsychotic medications, occurring in an estimated 20% of this population. This condition inflicts a substantial negative impact on patient quality of life and clinical outcomes and contributes to the significant rate of nonadherence to antipsychotic medication regimens.

Tardive Dyskinesia 360 is a resource center built for mental health practitioners, designed to educate providers on the proper screening, diagnosis, and treatment of TD. Explore expert video commentary, patient cases activities, instructional videos, and stay up to date on the latest information related to TD care.

This initiative is supported by independent educational grants from Neurocrine Biosciences and Teva Pharmaceuticals.

Videos

Abnormal Involuntary Movement Scale (AIMS) Exam
AIMS Exam Instructional Video
Psych Congress co-chair Rakesh Jain, MD, MPH, explains the importance of the Abnormal Involuntary Movement Scale (AIMS) exam in the diagnosis and monitoring of patients with tardive dyskinesia.
NULL
Abnormal Involuntary Movement Scale (AIMS) Exam
Comprehensive AIMS Scoring Samples Playlist
From normal (0) to severe (4), see what real tardive dyskinesia movements look like so you can better assess your patients.
Treatment Discussion Points
In-depth Discussion about Deutetrabenazine and Valbenazine
Drs. Jain and Kumar provide and in-depth analysis of two new VMAT2 inhibitors approved to treat tardive dyskinesia.
Click here to view the full video library

Articles

VMAT2 Inhibitor Shown to Improve Tardive Dyskinesia Symptoms
A selective vesicular monoamine transporter 2 (VMAT2) inhibitor can improve symptoms of moderate to severe tardive dyskinesia (TD), posters presented at Psych Congress suggest.
Do TD Medications Decrease the Effectiveness of Antipsychotics?
Psych Congress Steering Committee cochair Rakesh Jain, MD, MPH, discusses using tardive dyskinesia treatments in conjunction with antipsychotics.
FDA Approves Deutetrabenazine for Treatment of Tardive Dyskinesia
The US Food and Drug Administration has approved deutetrabenazine for the treatment of tardive dyskinesia in adults, Teva Pharmaceutical Industries announced.
Researchers Develop New Scale to Assess Tardive Dyskinesia Effects
Researchers have developed a new scale to measure the impacts tardive dyskinesia has on patients and their caregivers, according to a poster abstract presented at Psych Congress 2017.
Study Reveals Potential Tardive Dyskinesia Biomarkers
An analysis of blood serum has identified differences between patients with tardive dyskinesia (TD) and people who have not developed the movement disorder.

Posters

Addressing Involuntary Movements in Tardive Dyskinesia (AIM-TD): A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study of Deutetrabenazine for the Treatment of Moderate to Severe Tardive Dyskinesia (TD)
This trial will evaluate the efficacy, safety and tolerability of fixed-dose regimens of deutetrabenazine for the treatment of TD, which may facilitate dose titration and decrease treatment burden.
Deutetrabenazine Treatment Effect in Each Component of the Total Abnormal Involuntary Movement Scale (AIMS)
In patients with moderate/severe TD, deutetrabenazine was associated with a reduction in abnormal, involuntary movements in 6 of the 7 areas evaluated.
Deutetrabenazine Is Associated With an Improvement in Involuntary Movements in Patients With Tardive Dyskinesia (TD) as Seen by the High Proportion of Responders to Treatment in the ARM-TD Study
In ARM-TD, a higher proportion of deutetrabenazine patients were responders compared with placebo, defined by percent improvement on AIMS from baseline to Week 12.
KINECT 3: A Phase 3 Study of Valbenazine (NBI-98854) for the Treatment of Tardive Dyskinesia
KINECT 3 (NCT02274558), a 6-week, double-blind, placebo-controlled study, was conducted in subjects with moderate-to-severe TD and underlying schizophrenia, schizoaffective disorder, or mood disorder.
Tardive Dyskinesia: Patient and Caregiver Perspectives on Signs, Symptoms, and Impact
Concept elicitation interviewing techniques were utilized with patients and caregivers to elicit the TD experience, and cognitive interviewing techniques were utilized to test a patient-reported…
Back to Top